Detalles de la búsqueda
1.
A time-to-event analysis of the exposure-response relationship for bezlotoxumab concentrations and CDI recurrence.
J Pharmacokinet Pharmacodyn
; 47(2): 121-130, 2020 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-32048107
2.
Population Pharmacokinetics and Pharmacodynamics of Bezlotoxumab in Adults with Primary and Recurrent Clostridium difficile Infection.
Antimicrob Agents Chemother
; 63(2)2019 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-30455246
3.
Extending a Systems Model of the APP Pathway: Separation of ß- and γ-Secretase Sequential Cleavage Steps of APP.
J Pharmacol Exp Ther
; 365(3): 507-518, 2018 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-29563326
4.
Systems Pharmacology Analysis of the Amyloid Cascade after ß-Secretase Inhibition Enables the Identification of an Aß42 Oligomer Pool.
J Pharmacol Exp Ther
; 357(1): 205-16, 2016 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-26826190
5.
Model-Informed Selection of the Recommended Phase III Dose of the Inhibitor of Apoptosis Protein Inhibitor, Xevinapant, in Combination with Cisplatin and Concurrent Radiotherapy in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck.
Clin Pharmacol Ther
; 115(1): 52-61, 2024 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37777832
6.
Early stage development of the glycine-1 re-uptake inhibitor SCH 900435: central nervous system effects compared with placebo in healthy men.
Br J Clin Pharmacol
; 75(6): 1455-67, 2013 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-23116363
7.
Predicted Bezlotoxumab Exposure in Patients Who Have Received a Hematopoietic Stem Cell Transplant.
Clin Ther
; 45(4): 356-362, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36906440
8.
Population pharmacokinetic analysis of sparsentan in healthy volunteers and patients with focal segmental glomerulosclerosis.
CPT Pharmacometrics Syst Pharmacol
; 12(8): 1080-1092, 2023 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-37221817
9.
Population pharmacokinetic analyses for belzutifan to inform dosing considerations and labeling.
CPT Pharmacometrics Syst Pharmacol
; 12(10): 1499-1510, 2023 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37596839
10.
Eculizumab Pharmacokinetics and Pharmacodynamics in Patients With Neuromyelitis Optica Spectrum Disorder.
Front Neurol
; 12: 696387, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34803867
11.
Eculizumab Pharmacokinetics and Pharmacodynamics in Patients With Generalized Myasthenia Gravis.
Front Neurol
; 12: 696385, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34795626
12.
Population pharmacokinetic and exposure-response analyses of ivosidenib in patients with IDH1-mutant advanced hematologic malignancies.
Clin Transl Sci
; 14(3): 942-953, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33493392
13.
Design and rationale of two phase 3 randomised controlled trials (COUGH-1 and COUGH-2) of gefapixant, a P2X3 receptor antagonist, in refractory or unexplained chronic cough.
ERJ Open Res
; 6(4)2020 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-33263037
14.
Making Better Dose Decisions: Using Exposure-Response Modeling to Integrate Efficacy Outcome of Two Phase IIb Clinical Trials of Ubrogepant for Migraine Treatment.
Clin Transl Sci
; 13(3): 482-490, 2020 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-31758661
15.
Population PK Analyses of Ubrogepant (MK-1602), a CGRP Receptor Antagonist: Enriching In-Clinic Plasma PK Sampling With Outpatient Dried Blood Spot Sampling.
J Clin Pharmacol
; 58(3): 294-303, 2018 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-29136283
16.
A PK-PD model-based assessment of sugammadex effects on coagulation parameters.
Eur J Pharm Sci
; 84: 9-17, 2016 Mar 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-26747019
Resultados
1 -
16
de 16
1
Próxima >
>>